Funder: Crohn's and Colitis Foundation
Due Dates: May 31, 2026 (LOI) | August 14, 2026 (Full proposal)
Funding Amounts: Up to $450,000 per project for one year; potential renewal for additional $450,000 per year based on progress.
Summary: Supports companies developing innovative, non-surgical therapeutics for fibrosis in IBD patients, with a focus on translational, milestone-driven product development.
Key Information: LOI required before full proposal; both US and international companies eligible; academic collaborators allowed if focused on product development.